Mustang Bio, Inc. (MBIO)
MBIO Stock Price Chart
Explore Mustang Bio, Inc. interactive price chart. Choose custom timeframes to analyze MBIO price movements and trends.
MBIO Company Profile
Discover essential business fundamentals and corporate details for Mustang Bio, Inc. (MBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Aug 2017
Employees
6.00
Website
https://www.mustangbio.comCEO
Manuel Litchman
Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
MBIO Financial Timeline
Browse a chronological timeline of Mustang Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 6 Nov 2025
Earnings released on 8 Aug 2025
EPS came in at -$0.19 .
Earnings released on 14 May 2025
EPS came in at -$0.05 .
Earnings released on 24 Mar 2025
EPS came in at -$37.95 falling short of the estimated -$5.50 by -590.00%.
Stock split effective on 16 Jan 2025
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Nov 2024
EPS came in at -$2.00 surpassing the estimated -$6.50 by +69.23%.
Earnings released on 13 Aug 2024
EPS came in at -$12.00 falling short of the estimated -$7.00 by -71.43%.
Earnings released on 15 May 2024
EPS came in at -$23.00 falling short of the estimated -$0.87 by -2.54K%.
Earnings released on 11 Mar 2024
EPS came in at -$35.50 surpassing the estimated -$84.00 by +57.74%, while revenue for the quarter reached $2.88M .
Earnings released on 14 Nov 2023
EPS came in at -$61.50 surpassing the estimated -$94.00 by +34.57%.
Earnings released on 14 Aug 2023
EPS came in at -$100.00 surpassing the estimated -$103.50 by +3.38%.
Earnings released on 12 May 2023
EPS came in at -$103.00 surpassing the estimated -$142.50 by +27.72%.
Stock split effective on 4 Apr 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 29 Mar 2023
EPS came in at -$134.93 surpassing the estimated -$142.43 by +5.27%.
Earnings released on 14 Nov 2022
EPS came in at -$134.93 surpassing the estimated -$149.93 by +10.00%.
Earnings released on 11 Aug 2022
EPS came in at -$142.43 surpassing the estimated -$157.42 by +9.52%.
Earnings released on 12 May 2022
EPS came in at -$149.93 falling short of the estimated -$134.93 by -11.12%.
Earnings released on 23 Mar 2022
EPS came in at -$164.92 falling short of the estimated -$157.42 by -4.76%.
Earnings released on 12 Nov 2021
EPS came in at -$142.43 falling short of the estimated -$134.93 by -5.56%.
Earnings released on 16 Aug 2021
EPS came in at -$119.94 surpassing the estimated -$149.93 by +20.00%.
Earnings released on 14 May 2021
EPS came in at -$142.43 surpassing the estimated -$149.93 by +5.00%.
Earnings released on 24 Mar 2021
EPS came in at -$239.88 falling short of the estimated -$157.42 by -52.38%.
Earnings released on 6 Nov 2020
EPS came in at -$172.41 surpassing the estimated -$194.90 by +11.54%.
MBIO Stock Performance
Access detailed MBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.